Literature DB >> 24563349

Nuclear envelope regulation of signaling cascades.

Jason C Choi1, Howard J Worman.   

Abstract

The ultimate purpose of signal transduction is to transmit extracellular or cytoplasmic stimuli to the nuclear interior to elicit a cellular response, mediated primarily through changes in gene expression. The evolution of the nuclear envelope and the consequent compartmentalization of the genome, which is a defining feature of eukaryotes, introduced a physical barrier to the free access of genes. Initially regarded as nothing more than this, a physical barrier with selective permeability, recent findings have transformed our view of the nuclear envelope and its diverse roles in various aspects of cell biology and human diseases, much of which is only beginning to be understood. The realization that mutations in genes encoding nuclear envelope proteins cause a diverse array of tissue-selective diseases often referred to as "laminopathies" has provided new insight into structural and regulatory functions of the nuclear envelope. Genetic mutations causing abnormalities in the nuclear envelope can lead to dysregulated signaling that underlies pathogenesis of these diseases. The emerging picture indicates that the nuclear envelope is a node that fine-tunes signaling output and as such it may play a role in the biology of cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24563349     DOI: 10.1007/978-1-4899-8032-8_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

Review 1.  Messages from the voices within: regulation of signaling by proteins of the nuclear lamina.

Authors:  Larry Gerace; Olga Tapia
Journal:  Curr Opin Cell Biol       Date:  2018-01-04       Impact factor: 8.382

2.  Nucleoskeletal regulation of transcription: Actin on MRTF.

Authors:  Ekaterina Sidorenko; Maria K Vartiainen
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-29

Review 3.  Intermediate filaments in cardiomyopathy.

Authors:  Mary Tsikitis; Zoi Galata; Manolis Mavroidis; Stelios Psarras; Yassemi Capetanaki
Journal:  Biophys Rev       Date:  2018-07-19

4.  N7-Methylguanosine Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.

Authors:  Parbatraj Regmi; Zhi-Qiang He; Thongher Lia; Aliza Paudyal; Fu-Yu Li
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

5.  Identifying Protein-Protein Associations at the Nuclear Envelope with BioID.

Authors:  Dae In Kim; Samuel C Jensen; Kyle J Roux
Journal:  Methods Mol Biol       Date:  2016

6.  Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.

Authors:  Erlene K Seymour; Husain Yar Khan; Yiwei Li; Mahmoud Chaker; Irfana Muqbil; Amro Aboukameel; Radhakrishanan Ramchandren; Christiane Houde; Golbon Sterbis; Jay Yang; Divaya Bhutani; Silvana Pregja; Kathy Reichel; Amy Huddlestun; Colleen Neveux; Kelly Corona; Yosef Landesman; Jatin Shah; Michael Kauffman; Sharon Shacham; Ramzi M Mohammad; Asfar S Azmi; Jeffrey A Zonder
Journal:  Clin Cancer Res       Date:  2021-03-30       Impact factor: 12.531

Review 7.  Lamins at the crossroads of mechanosignaling.

Authors:  Selma Osmanagic-Myers; Thomas Dechat; Roland Foisner
Journal:  Genes Dev       Date:  2015-02-01       Impact factor: 11.361

Review 8.  Role of Lamin A/C Gene Mutations in the Signaling Defects Leading to Cardiomyopathies.

Authors:  Andrea Gerbino; Giuseppe Procino; Maria Svelto; Monica Carmosino
Journal:  Front Physiol       Date:  2018-09-25       Impact factor: 4.566

9.  Shared and Distinctive Neighborhoods of Emerin and Lamin B Receptor Revealed by Proximity Labeling and Quantitative Proteomics.

Authors:  Li-Chun Cheng; Xi Zhang; Kanishk Abhinav; Julie A Nguyen; Sabyasachi Baboo; Salvador Martinez-Bartolomé; Tess C Branon; Alice Y Ting; Esther Loose; John R Yates; Larry Gerace
Journal:  J Proteome Res       Date:  2022-08-16       Impact factor: 5.370

10.  Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Authors:  Irfana Muqbil; Amro Aboukameel; Sivan Elloul; Robert Carlson; William Senapedis; Erkan Baloglu; Michael Kauffman; Sharon Shacham; Divaya Bhutani; Jeffrey Zonder; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancer Lett       Date:  2016-09-28       Impact factor: 8.679

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.